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use#LAAGlaucoma is a chronic neurodegenerative disease in 
which retinal ganglion cells (RGCs) degenerate, leading to 
gradual vision loss and ultimately blindness. RGC death is 
commonly, but not always, associated with elevated intra-
ocular pressure (IOP). Conditions such as neurotrophin 
deprivation, glial activation, ischemia, oxidative stress, and 
excitotoxicity have been suggested to play a role in glaucoma 
(reviewed in [1]). Ultimately, RGCs appear to die by apop-
tosis. Calcineurin is a Ca2+/calmodulin-dependent serine/
threonine phosphatase. It is widely expressed in mammalian 
tissues including the retina [2,3], brain [4,5], and immune 
cells [6]. In neurons, calcineurin is involved in morphological 
neurodegeneration [7] and apoptosis [8-11]. We recently 
suggested that activation of calcineurin acts as a key initiating 
step of apoptotic pathways in RGCs in mouse and rat models 
of elevated IOP. This hypothesis was based on observations 
that a constitutively active truncated form of calcineurin 
was present in these models, and blocking calcineurin with 
a pharmacological inhibitor, FK506, was neuroprotective 
[12]. However, FK506 has some off-target effects [13], so it 
remains formally possible that FK506 protection is not due to 
inhibition of calcineurin. To further test the model that calci-
neurin activation is a critical component of neurodegenerative 
cascades in RGCs, we tested the prediction that activating 
calcineurin, even without elevated intraocular pressure, 
would lead to a phenotype of RGC degeneration similar to 
that seen in models of glaucoma.
In a primate model of glaucoma, retinal parasol cells 
from glaucomatous eyes had a smaller soma, a smaller and 
less complex dendritic arbor, and a shorter total dendrite 
length [14]. In DBA/2J mice, a mouse strain that spontane-
ously develops glaucoma, dendritic degeneration and somal 
shrinkage precede RGC death [15]. In addition, there is 
progressive RGC axon loss in the optic nerve as glaucoma 
progresses [16]. In the mouse and rat experimental glaucoma 
models, calcineurin is activated in glaucomatous eyes as 
judged by the presence of truncated constitutively activated 
calcineurin [12]. In this study, we tested the hypothesis 
that calcineurin activation causes RGC somal, dendritic, 
and axonal degeneration similar to glaucomatous RGC 
degeneration.
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Calcineurin activation causes retinal ganglion cell degeneration
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Purpose: We previously reported that calcineurin, a Ca2+/calmodulin-dependent serine/threonine phosphatase, is ac-
tivated and proposed that it participates in retinal ganglion cell (RGC) apoptosis in two rodent ocular hypertension 
models. In this study, we tested whether calcineurin activation by itself, even in the absence of ocular hypertension, is 
sufficient to cause RGC degeneration.
Methods: We compared RGC and optic nerve morphology after adeno-associated virus serotype 2 (AAV2)–mediated 
transduction of RGCs with constitutively active calcineurin (CaNCA) or unactivated, wild-type calcineurin (CaNwt). 
Retinas and optic nerves were harvested 7–16 weeks after injection of the AAV into mouse vitreous. In flatmounted 
retinas, the transduced RGCs were identified with immunohistochemistry. The morphology of the RGCs was revealed 
by immunostaining for neurofilament SMI32 or by using GFP-M transgenic mice. A modified Sholl analysis was applied 
to analyze the RGC dendritic morphology. Optic nerve damage was assessed with optic nerve grading according to the 
Morrison standard.
Results: CaNwt and CaNCA were highly expressed in the injected eyes. Compared to the CaNwt-expressing RGCs, the 
CaNCA-expressing RGCs had smaller somas, smaller dendritic field areas, shorter total dendrite lengths, and simpler 
dendritic branching patterns. At 16 weeks, the CaNCA-expressing eyes had greater optic nerve damage than the CaNwt-
expressing eyes.
Conclusions: Calcineurin activation is sufficient to cause RGC dendritic degeneration and optic nerve damage. These 
data support the hypothesis that calcineurin activation is an important mediator of RGC degeneration, and are consistent 
with the hypothesis that calcineurin activation may contribute to RGC neurodegeneration in glaucoma.
Correspondence to: Cynthia L. Grosskreutz, Massachusetts Eye and 
Ear Infirmary 243 Charles St., Boston, MA 02114; Phone: (617) 
573-6487; FAX: (617) 573-3707; email: cynthia_grosskreutz@meei.
harvard.edu
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Wild-type calcineurin contains a catalytic domain and 
an autoinhibitory domain. Under physiologic conditions, 
the autoinhibitory domain blocks the catalytic domain and 
inhibits enzyme activity in the absence of Ca2+/calmodulin. 
Upon binding of Ca2+/calmodulin, calcineurin undergoes a 
conformational change, exposes the catalytic domain, and 
activates the enzyme [4,17]. Under pathological conditions, 
the autoinhibitory domain can be cleaved by proteases such 
as calpain [8,18], leaving the catalytic domain constitutively 
active (Figure 1A). We used adeno-associated virus serotype 
2 (AAV2) to deliver wild-type calcineurin and constitutively 
active (C-terminal autoinhibitory domain truncated [7]) calci-
neurin to RGCs in vivo. We found that constitutively active 
calcineurin caused more RGC morphological degeneration 
and optic nerve damage than wild-type calcineurin, which 
did not differ from control injections of AAV2. These data 
suggest that calcineurin activation is a critical mediator of 
RGC degeneration, and are consistent with the hypothesis that 
calcineurin activation in models of glaucoma is an important 
part of the cascade of events that lead to RGC degeneration.
METHODS
Animals: All experiments were performed in accordance with 
the ARVO Statement for the Use of Animals in Ophthalmic 
and Vision Research. In human patients and in spontaneous 
animal models [14-16], glaucoma is more prevalent in an aged 
population. To make our results comparable, we conducted 
our studies on nine- to 12-month-old female C57BL/6 mice 
(Charles River Laboratories, Boston, MA) and 12-month-old 
female GFP-M mice (Strain name Tg(Thy1-EGFP)MJrs/J, 
The Jackson Laboratory, Bar Harbor, ME). Similar to the 
Thy1-YFP mice used in a previous RGC morphology study 
[19], in GFP-M mice a small proportion of RGCs express 
green fluorescent protein (GFP) in their somas, axons, and 
dendrites [20]. The sparse labeling of RGCs avoids overlap 
of dendrites of neighboring labeled cells, thus allowing clear 
visualization of the entire dendritic arbor in each individual 
RGC.
Intravitreal injection: AAV serotype 2 was used to express 
calcineurin in RGCs because the virus primarily transduces 
RGCs when administrated intravitreally. Three AAVs 
carrying 1) enhanced green fluorescent protein (EGFP), 2) 
hemagglutinin (HA)-tagged mouse wild-type calcineurin 
(CaNwt), and 3) an HA-tagged constitutively active truncated 
form of calcineurin (CaNCA) were used in this study (Figure 
1B). The detailed structures of the AAV vectors were previ-
ously described by Wu and colleagues [7]. Briefly, EGFP, 
HA-CaNwt, and HA-CaNCA (amino acid residues 1–399) 
were cloned into rAAV-cytomegalovirus immediate-early 
enhancer/chicken beta-actin promoter-woodchuck posttran-
scriptional regulatory element vector. High-titer AAV2 was 
produced using plasmid triple transfection. The expression of 
EGFP was readily visible under a confocal microscope. The 
expression of CaNwt and CaNCA was revealed with immu-
nohistochemistry using an antibody against their N-terminal 
HA tag. All three AAVs had similar transduction rates.
Mice were anesthetized with a mixture of ketamine 
(100 mg/kg) and xylazine (10 mg/kg) (both from Webster 
Veterinary Supply, Sterling, MA). One drop of 0.5% propara-
caine was applied topically for local anesthesia. Using a glass 
needle (tip diameter about 50 μm), 1 μl of virus (titer, 2×1012 
viral genomes/ml) was injected into the vitreous at about 
1 mm behind the limbus. AAV2 is known to have a relative 
tropism for RGCs in the retina. After the injection, antibiotic 
ointment was applied, and the mice recovered from anesthesia 
on a heating pad.
Tissue harvesting: Mice were overdosed with a mixture of 
ketamine and xylazine (i.p. 300 mg/kg and 30 mg/kg, respec-
tively), the eyes were enucleated, and the mice were eutha-
nized immediately by cervical dislocation. The retinas were 
dissected in PBS (8.06 mM Na2HPO4, 1.94 mM KH2PO4, 2.7 
mM KCl, 137 mM NaCl), flatmounted on filter paper and 
fixed in 4% paraformaldehyde for 2 h, washed in PBS and 
stored at 4 °C. The optic nerves were fixed in 2.5% glutaral-
dehyde and 2% formaldehyde in 0.1 M cacodylate buffer with 
0.08 M CaCl2 at 4 °C overnight, washed in 0.1 M cacodylate 
buffer, and stored at 4 °C.
Immunohistochemistry: Flatmounted retinas were blocked 
in 4% normal goat serum (Invitrogen, Eugene, OR) in PBS 
at 4 °C overnight, incubated in rabbit anti-HA (1:200, Invit-
rogen) and/or mouse anti-SMI32 (1:100, Covance, Emeryville, 
CA) at 4 °C for 1 week, rinsed in PBS, and incubated in Alexa 
488 or 594 conjugated goat antirabbit (1:250, Invitrogen) and/
or goat antimouse (1:500, Invitrogen) antibodies at 4 °C for 
1 week, rinsed in PBS, and mounted with Prolong Gold anti-
fade reagent (Invitrogen). Images were taken with a Bio-Rad 
Radiance laser scanning confocal microscope (Hercules, CA) 
and edited in ImageJ (National Institutes of Health, Bethesda, 
MD).
Optic nerve grading: The optic nerve was post-fixed for 1.5 
h in 2% aqueous OsO4, dehydrated in graded ethanols, tran-
sitioned in propylene oxide, infiltrated with propylene oxide 
and epon mixtures (Tepon resin, Tousimis, Rockville, MD), 
embedded in epon, and cured for 24–48 h at 60 °C. One-
micron sections were cut in a plane perpendicular to the axis 
of the nerve on a Leica Ultracut UCT (Buffalo Grove, IL) and 
stained with 1% toluidine blue in 1% borate buffer. Images 
tiling the entire optic nerve were taken with an Olympus Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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Figure 1. AAV2-mediated transduc-
tion was used to study calcineurin 
function in mouse retinal ganglion 
cells (RGCs). A: Calcineurin can 
be activated under physiologic 
conditions or pathological condi-
tions [8]. Under physiologic condi-
tions, binding of Ca2+/calmodulin 
reversibly exposes the catalytic 
domain and activates the enzyme. 
Under pathological conditions, 
cleavage of the autoinhibitory 
domain leaves the catalytic domain 
constitutively active. B: Three 
AAVs were used to express EGFP 
(control), HA-tagged full-length 
calcineurin (CaNwt, unactivated), 
and HA-tagged cleaved calcineurin 
(CaNCA, constitutively active) in 
RGCs. C: EGFP was expressed in 
RGCs throughout the retina nine 
weeks after intravitreal injection of 
AAV-EGFP.Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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BX51 microscope (Albertslund, Denmark). Images from the 
experimental eyes and control eyes were masked, randomly 
mixed, and then graded by four well-trained observers using 
the Morrison standard [21]. The average grades from the four 
observers were taken as the grades of the optic nerves.
Morphological analysis: The right eye and the left eye of 
three 12-month-old GFP-M mice were injected with AAVs 
carrying CaNwt and CaNCA, respectively. The mice were 
sacrificed 16 weeks after the injection, and the retinas were 
flatmounted. Image stacks of GFP-expressing RGCs were 
taken with a Bio-Rad Radiance laser scanning confocal 
microscope. The z-projections of the image stacks were 
manually traced in an ImageJ plugin NeuronJ. The trac-
ings were then used for all the morphological analyses. In 
total, there were 23 CaNwt/GFP double-labeled RGCs, and 
31 CaNCA/GFP double-labeled RGCs with a well-defined 
dendritic arbor. The distribution was even, and we did not 
see a significant difference among the RGCs collected from 
the three mice. Therefore, the data were combined for the 
morphological analyses except the Wilcoxon rank-sum test, 
where the permutations were performed within each mouse.
The total length of the RGC dendrites was measured in 
NeuronJ. The areas of the RGC soma and dendritic fields 
were measured using a custom ImageJ macro. Sholl analysis 
was performed to evaluate the complexity of the RGC 
dendrites using the same macro. For each RGC, Sholl analysis 
was performed by counting the number of dendrite intersec-
tions with concentric circles of gradually increasing radius 
centered on the centroid of the soma. The number of intersec-
tions was plotted against the radius, and the area under the 
curve (AUC) was calculated using the trapezoidal method. 
We used the AUC as we had hypothesized that it would be 
a powerful test statistic for distinguishing between the two 
conditions that achieved 0 intersections at similar radii, but 
for which one had consistently more intersections at a set of 
smaller radii. The Wilcoxon rank-sum test was then used to 
compare the AUCs for the CaNwt and CaNCA conditions. 
Because each mouse contributed several AUCs to each condi-
tion, we could not use the standard p value calculation for the 
Wilcoxon test that assumes independence among observa-
tions. Instead, we calculated the p value based on a permuta-
tion approach. Wo was the Wilcoxon test statistic comparing 
CaNwt and CaNCA for the original data set. Wperm was the 
Wilcoxon test statistic for permuted data; within each mouse, 
we permuted the labels of CaNwt and CaNCA, keeping the 
Sholl plots for each condition intact and the number of each 
condition for each mouse fixed. For each permutation, we 
calculated a Wilcoxon test statistic. The permutations were 
repeated 2,000 times to obtain a null permutation distribution 
of the Wilcoxon test statistics, to which we compared the 
actual obtained value, Wo. The permutation p value is the 
estimated probability of Wperm > Wo and represents the prob-
ability of observing the value that we observed under the null 
hypothesis of no difference between conditions. The null 
hypothesis was rejected when the permutation p value <0.05. 
Although Wo and Wperm were calculated on RGCs pooled from 
all the mice, the permutation was performed independently 
within each mouse, a more conservative estimate since the 
RGCs from the left eye and the right eye of an individual 
mouse may be more alike than the RGC characteristics in 
retinas from different mice.
RESULTS
Calcineurin activation caused neurofilament degeneration 
in retinal ganglion cell dendrites: AAVs carrying HA-tagged 
mouse wild-type calcineurin (CaNwt) or an HA-tagged 
truncated form of calcineurin (CaNCA) were injected intra-
vitreally into one eye of the C57Bl/6 mice. The other eye 
was injected with an AAV carrying EGFP as a control. The 
wild-type calcineurin (CaNwt) contains the catalytic domain 
and the inhibitory domain; therefore, CaNwt activity is under 
biologic control. In contrast, the truncated form of calcineurin 
(CaNCA) does not contain the autoinhibitory domain and is 
constitutively active (Figure 1B). As shown in Figure 1C, 
EGFP was expressed in retinal ganglion cells throughout the 
retina. CaNwt and CaNCA had similar expression patterns, 
revealed by immunostaining against their HA tag (data not 
shown).
Immunohistochemistry against neurofilament SMI32 
labels a subpopulation of RGCs in the retina [15]. SMI32 
immunoreactivity (SMI32-IR) is detectable in RGC somas, 
dendrites, and axons. Seven weeks after AAV injection, 
compared to the EGFP-expressing retinas, SMI32-IR was 
clearly reduced in the RGC dendrites, especially in the 
higher-order dendrites, in the CaNCA-expressing retinas 
(six mice). The SMI32-IR in RGC dendrites in the CaNwt-
expressing retinas (six mice) was still extensive and was not 
different from the control EGFP-expressing retinas (Figure 
2A). The SMI32-IR in RGC somas and axons did not show a 
consistent change either in the CaNwt-expressing retinas or in 
the CaNwt-expressing retinas. Results were similar 16 weeks 
after AAV injection (six mice for CaNwt/EGFP and six mice 
for CaNCA/EGFP) (Figure 2B). The reduction in SMI32-IR 
in the RGC dendrites indicated degradation of the neurofila-
ments, and suggested that calcineurin activation could cause 
degeneration of RGC dendrites.
Calcineurin  activation  caused  degeneration  of 
retinal ganglion cell somas and dendrites: Although Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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Figure 2. Calcineurin activation 
caused neurofilament degen-
eration in retinal ganglion cell 
(RGC) dendrites. C57BL/6 mice 
were intravitreally injected with 
AAV carrying EGFP (control), 
HA-tagged full-length calci-
neurin (CaNwt), and HA-tagged 
cleaved calcineurin (CaNCA). The 
expression of transduced CaNwt 
and CaNCA was revealed by the 
antibody against their HA tag. 
RGC dendritic morphology was 
assessed with immunohistochem-
istry against SMI32. Seven weeks 
(A) and sixteen weeks (B) after 
injection, SMI32-IR was reduced 
in RGC dendrites in the CaNCA-
expressing retinas at both time 
points, but not in the EGFP- or 
CaNwt-expressing retinas. The 
arrowheads point at the dendrites 
in EGFP- or CaNwt-expressing 
RGCs. No consistent difference 
was observed in SMI32-IR in RGC 
somas and axons. Scale bars are 
50 µm.Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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immunohistochemistry of SMI32 is commonly used to study 
RGC morphology, it has certain limitations. The antibody 
against SMI32 labels only the nonphosphorylated form of 
neurofilament H; therefore, the phosphorylation state can 
affect the SMI32-IR. In addition, the overlap of the dendrites 
from neighboring SMI32-positive RGCs interferes with 
analysis of higher-order dendrites. To assess whether the loss 
of SMI32-IR reflected a loss of dendritic structure or just a 
change in neurofilament phosphorylation, and to evaluate the 
entire dendritic arbor more precisely, we repeated the experi-
ment using GFP-M transgenic mice [20] for morphological 
analysis. In the retina of GFP-M mice, a small proportion 
of RGCs express GFP, allowing visualization of the entire 
dendritic arbor (Figure 3A) in those cells. AAVs carrying 
CaNwt and CaNCA were injected into the right eye and 
the left eye, respectively, of the GFP-M mice. These GFP-
expressing RGCs were imaged and manually traced if (1) 
there was a clear axon confirming the identity of the cell as 
an RGC and (2) the soma contained HA immunoreactivity 
indicating that the RGC had been transduced with the AAV. 
The digital tracings were used for all the following quantita-
tive morphological analyses (Figure 3B).
Sixteen weeks after AAV injection, compared to the 
CaNwt-expressing RGCs (n=23), the CaNCA-expressing 
RGCs (n=31) had smaller somas (Figure 3D; CaNCA 
342±18 µm2 versus CaNwt 434±31 µm2, p=0.008; all results 
are mean±standard error, two-tailed unpaired Student t 
test) and smaller dendritic field areas (Figure 3E; CaNCA 
67209±7257 µm2 versus CaNwt 89805±9203 µm2, p=0.056). 
In the CaNwt-expressing RGCs and the CaNCA-expressing 
RGCs, there was a direct correlation between the size of 
the RGC soma and the size of the dendritic field, i.e., RGCs 
with smaller somas usually had smaller dendritic fields, and 
RGCs with larger somas usually had larger dendritic fields 
(Figure 3G). However, although the CaNwt-expressing RGCs 
had relatively even distribution among all sizes, the CaNCA-
expressing RGCs clustered in the lower left corner of the 
graph (Figure 3G), suggesting they had smaller somas and 
smaller dendritic fields.
Sholl analysis was applied on the RGC tracings to 
quantitatively evaluate the effects of calcineurin activation 
on the complexity of the RGC dendrites. The analysis was 
performed by counting the number of dendrite intersec-
tions with concentric circles of gradually increasing radius 
centered on the centroid of the soma (Figure 3B). As shown 
in Figure 3H, there was no difference in the number of 
intersections between the CaNwt- and CaNCA-expressing 
RGCs within 60 µm to the soma centroid, but there were 
significantly fewer intersections in the CaNCA-expressing 
RGCs 80 µm and further from the soma. This indicated 
that although the number of primary dendrites had not been 
affected at 16 weeks, the number of higher-order dendritic 
branches was significantly reduced by calcineurin activation. 
To capture the overall complexity of the RGC dendrites, we 
used a novel AUC approach to analyze the data, followed 
by a Wilcoxon rank-sum test to assess significance (see 
the Methods section for details). The permutation p value 
of 0.012 indicates that there is a statistically significant 
difference between CaNCA-expressing RGCs compared to 
CaNwt-expressing RGCs, with CaNCA leading to a substan-
tial decrease in dendritic complexity. Another measure of 
dendritic structure was also employed: adding the length of 
all the dendritic segments together. The CaNCA-expressing 
RGCs had significantly shorter total dendrite lengths (Figure 
3F; CaNCA 3473±216 µm versus CaNwt 4652±306 µm, 
p=0.002). This is likely due to the shrinkage of higher-order 
dendrites, consistent with the Sholl analysis results.
All the HA-positive RGCs with clearly GFP-labeled 
dendrites were traced and included in the analyses in the 
AAV-injected GFP-M mice (Figure 3A). However, rare RGCs 
expressed GFP in the somas, but their dendrites, especially 
the higher-order dendrites, were invisible (Figure 3C). These 
RGCs were excluded from the morphological analyses. In our 
experience working with GFP-M mice (young and old), well-
labeled RGCs show clear endings of the terminal dendrites, 
i.e., the dendrite terminals end abruptly instead of gradually 
fading away. In the case when an RGC weakly expresses GFP, 
the soma (where the GFP concentrates) still shows up, but the 
dendritic tree can range from faint to invisible. When immu-
nohistochemistry against GFP is performed, some of these 
faint/invisible dendrites can become visible. Therefore, the 
lack of clear dendrites could indicate complete degeneration 
of the dendrites, but could also be due to the low expression 
level of GFP. Because these cells are more often encountered 
in CaNCA-expressing retinas than in CaNwt-expressing 
retinas, by excluding them, the statistically significant effects 
of calcineurin activation on RGC morphological degeneration 
reported above could actually be an underestimation.
Calcineurin activation caused optic nerve damage: The 
axons of RGCs bundle together and form the optic nerve. In 
glaucoma, these axons degenerate as the disease progresses 
[16]. We found that extended activation of calcineurin 
also caused RGC axon degeneration in the optic nerve. In 
C57BL/6 mice seven weeks after intravitreal injection of 
AAVs carrying EGFP, CaNwt, or CaNCA, the optic nerves 
from the EGFP-expressing eyes and the CaNwt-expressing 
eyes were morphologically normal, while the optic nerves 
from the CaNCA-expressing eyes had some degenerating Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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Figure 3. Calcineurin activation caused retinal ganglion cell (RGC) somal shrinkage and dendritic degeneration. GFP-M mice were intravit-
really injected with AAV carrying full-length calcineurin (CaNwt) in one eye and AAV carrying cleaved calcineurin (CaNCA) in the other 
eye. A: A sample GFP-expressing RGC displayed well labeled dendrites. Arrowheads point at the axon. B: The RGC in (A) was digitally 
traced in NeuronJ. Soma area, dendritic field area, and total dendrite length were measured. Sholl analysis was applied. C: A few RGCs had 
GFP-expressing soma, but the higher-order dendrites or the entire dendritic tree were not visible. These RGCs were rare, but more in the 
CaNCA-expressing retinas. They were not included in the morphological analysis. D: RGCs had smaller soma areas in the CaNCA-expressing 
retinas. (All results were mean±standard error of the mean, two-tailed unpaired Student t test). E: RGCs had smaller dendritic field areas 
in the CaNCA-expressing retinas. F: RGCs had shorter total dendrite length in the CaNCA expressing retinas. G: The soma areas of all 
the RGCs were plotted against the dendritic field areas. The CaNCA-expressing RGCs cluster in the lower-left corner, which indicates they 
had smaller soma areas and smaller dendritic field areas. H: Sholl analysis showed fewer RGC dendritic branches were present in CaNCA-
expressing retinas. (*p<0.05, two-tailed unpaired Student t test).Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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axons (Figure 4A). Sixteen weeks after AAV injection, the 
optic nerves from the EGFP-expressing eyes and the CaNwt-
expressing eyes still looked healthy, but the optic nerves from 
the CaNCA-expressing eyes had notably more degenerating 
axons (Figure 4B).
To quantitatively evaluate the condition of the optic 
nerves, we adapted a grading system from the Morrison 
standard [21]. The images of the optic nerves were masked 
and graded by four trained observers, and the average was 
taken as the grade of each optic nerve. Healthy optic nerves 
received lower grades while more degenerated optic nerves 
received higher grades. The grades of the CaNwt-expressing 
eyes (five mice, seven weeks; five mice, 16 weeks) and the 
grades of the CaNCA-expressing eyes (six mice, seven weeks; 
five mice, 16 weeks) were normalized to the grades of their 
contralateral EGFP-expressing eyes. There was no significant 
difference between the CaNwt- and CaNCA- expressing eyes 
at seven weeks (two-tailed unpaired Student t test, p=0.13), 
Figure 4. Prolonged calcineurin 
activation caused optic nerve 
damage. A and B: Sample optic 
nerve images showed healthy and 
degenerated axons seven weeks (A) 
and 16 weeks (B) after AAV injec-
tion. Arrows point at degenerated 
retinal ganglion cell axons. Scale 
bar is 10 µm. C and D: The optic 
nerve degeneration was assessed 
by optic nerve grading using the 
Morrison standard. Higher grades 
were assigned to more damaged 
optic nerves. The optic nerve 
grades of the full-length calcineurin 
(CaNwt)-expressing eyes and the 
cleaved calcineurin (CaNCA)-
expressing eyes were normalized 
to their contralateral control EGFP-
expressing eyes. The optic nerves in 
the CaNCA-expressing eyes were 
not different from the CaNwt-
expressing eyes seven weeks after 
AAV injection (C), but were more 
damaged 16 weeks after AAV 
injection (D; two-tailed unpaired 
Student t test).Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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but the grades of the CaNCA-expressing eyes were signifi-
cantly higher 16 weeks after injection (p=0.00007; Figure 4C, 
D). This indicated that prolonged activation of calcineurin 
caused optic nerve damage.
Neurofilament degradation in RGC dendrites was 
already apparent seven weeks after AAV injection, while 
axon degeneration did not become significant (at least at the 
level of our observation) until much later. This suggested that 
calcineurin-caused RGC damage was likely to originate from 
the soma, and it might take longer for the effects to reach the 
axons in the optic nerve.
DISCUSSION
Calcineurin activation is an important mediator of retinal 
ganglion cell death in glaucoma: We previously demonstrated 
that calcineurin is activated in response to ocular hyperten-
sion in rat and mouse models of experimental glaucoma [12]. 
Activated calcineurin dephosphorylates Bcl-2-associated 
death promoter protein (BAD) and promotes cytochrome c 
release and RGC death [12]. As a Ca2+/calmodulin-dependent 
phosphatase, calcineurin can be directly activated by elevated 
intracellular calcium concentration. In glaucoma, many 
insults such as excitotoxicity [22], ischemia [23,24], and 
activation of the transient receptor potential cation channel, 
subfamily V, member 1 (TRPV1) [25] can lead to an increase 
in intracellular calcium concentration and therefore activate 
calcineurin. The increase in intracellular calcium can also 
activate Ca2+-dependent proteases such as calpain, which 
cleaves off the autoinhibitory domain of calcineurin and 
causes prolonged irreversible activation of calcineurin [7]. 
Inhibitors of calpain are neuroprotective in experimental 
glaucoma [26-28]. We have shown that calpain-mediated 
cleavage of calcineurin occurs in experimental glaucoma [8] 
and that inhibitors of calcineurin [29,30] are effective neuro-
protective agents in experimental glaucoma. Our data in this 
study show that even in the absence of ocular hypertension, 
calcineurin activation itself can cause RGC somal shrinkage 
and dendritic degeneration (Figure 2 and Figure 3), and optic 
nerve damage (Figure 4), similar to the RGC degeneration 
that happens in glaucomatous DBA/2J mice [15,16] and in 
primate models [14]. This further supports our hypothesis 
that calcineurin activation is an important mediator of RGC 
death in glaucoma.
Retinal ganglion cell degeneration is not restricted to one or 
a few retinal ganglion cell subtypes: More than a dozen RGC 
subtypes are present in the mouse retina [31-33]. Although 
some studies indicate that large RGCs are more vulnerable 
than small RGCs in human glaucoma [34,35], no subtypes of 
RGCs have been found to be especially vulnerable or resistant 
to degeneration in DBA/2J mice [15]. This could be due to 
differences among species, but it is also possible that RGC 
shrinkage is a generalized response in glaucoma leading to 
the impression of the disappearance of large RGCs and the 
persistence of small RGCs observed in earlier studies.
The latter interpretation is supported by a recent long-
term in vivo imaging study. Leung and colleagues serially 
recorded the morphological degeneration of 125 RGCs for 
six months after optic nerve crush using a confocal scanning 
laser ophthalmoscope [19]. The researchers found that essen-
tially all RGCs degenerate after optic nerve crush. The RGC 
degeneration begins with dendritic shrinkage and is followed 
by somal and axonal loss. This agrees well with our observa-
tions on RGC degeneration induced by calcineurin activation. 
Dendritic degeneration was already apparent seven weeks 
after AAV injection, but axonal degeneration could not be 
detected using our current techniques until much later. In 
Figure 3G, compared to the CaNwt-expressing RGCs, the 
distribution of the CaNCA-expressing RGCs appeared to shift 
to the lower-left corner of the graph, supporting the hypoth-
esis that all RGCs degenerate and shrink in size.
Our previous data [12] show that elevated IOP causes 
activation of calcineurin in RGC, and the current data suggest 
that RGC degeneration follows activation of calcineurin even 
without elevated IOP. These results suggest that calcineurin 
activation may be a critical mediator of RGC degeneration 
in glaucoma, and raise the interesting possibility that low-
tension glaucoma may be consequent to activation of calci-
neurin by a mechanism separate from elevation of IOP. Since 
calcineurin can be activated in various pathophysiological 
settings, calcineurin activation may lead to a common pheno-
type recognized clinically as glaucoma; if so, neuroprotective 
strategies targeting calcineurin or its downstream effec-
tors may be useful in low- and high-tension glaucomatous 
degeneration.
Summary: In sum, we observed a slowly progressive loss of 
dendritic complexity, somal shrinkage, and dendritic and 
axonal loss after transduction of RGC in normal mice with 
constitutively activated calcineurin. These changes closely 
reflected the phenotype seen in models of elevated intra-
ocular pressure, in which activation of calcineurin had been 
postulated to contribute to RGC neurodegeneration. Taken 
together with previous data demonstrating the presence of 
activated calcineurin in the setting of surgically induced 
ocular hypertension and a genetic model of glaucoma [12], 
the current data using AAV-mediated local gene expression 
in RGC strongly support a role for calcineurin in glauco-
matous damage. Therefore, blocking calcineurin activity is Molecular Vision 2012; 18:2828-2838 <http://www.molvis.org/molvis/v18/a999> © 2012 Molecular Vision 
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potentially a promising neuroprotective method in treating 
glaucoma.
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